Edwards Lifesciences Corporation
EW
$67.95
-$0.56-0.82%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.43% | 8.93% | 7.12% | 8.82% | -6.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.43% | 8.93% | 7.12% | 8.82% | -6.07% |
| Cost of Revenue | 16.41% | 4.91% | 11.90% | 23.97% | -2.68% |
| Gross Profit | 7.70% | 9.94% | 6.01% | 5.20% | -6.88% |
| SG&A Expenses | 18.27% | 10.34% | 10.22% | 13.30% | 1.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 87.10% | -- | -100.00% | -- | -- |
| Total Operating Expenses | 40.87% | 9.69% | -4.12% | 10.54% | -18.61% |
| Operating Income | -33.71% | 7.12% | 54.89% | 4.38% | 19.09% |
| Income Before Tax | 6.24% | 3.92% | 41.39% | 7.42% | -20.05% |
| Income Tax Expenses | 32.26% | -22.77% | -2.96% | 2.87% | -44.01% |
| Earnings from Continuing Operations | 3.57% | 8.12% | 45.00% | 8.11% | -16.39% |
| Earnings from Discontinued Operations | 7.38% | 5,447.75% | -94.97% | -36.55% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 550.00% | 16.67% | -18.75% | -- | -- |
| Net Income | 4.24% | 697.82% | 19.28% | 3.35% | -7.15% |
| EBIT | -33.71% | 7.12% | 54.89% | 4.38% | 19.09% |
| EBITDA | -30.51% | 5.88% | 48.99% | 4.84% | 17.97% |
| EPS Basic | 6.97% | 710.91% | 20.24% | 4.37% | -5.97% |
| Normalized Basic EPS | -29.27% | 15.87% | 53.27% | 8.73% | 19.97% |
| EPS Diluted | 7.08% | 716.06% | 19.57% | 4.98% | -6.06% |
| Normalized Diluted EPS | -29.16% | 16.18% | 53.57% | 8.86% | 20.27% |
| Average Basic Shares Outstanding | -2.54% | -1.61% | -0.79% | -0.99% | -1.26% |
| Average Diluted Shares Outstanding | -2.70% | -1.87% | -0.98% | -1.11% | -1.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
